Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 4/20 | 0.46 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.42 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.39 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.39 |
| ▸ | P2RY12 | Q9H244 | 7/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8380846 | 0.90 | TYMP (0.51) | TYMPPRMT6ADORA2AADORA2BP2RY12 | |
| SCHEMBL20637782 | 0.89 | TYMP (0.44) | TYMPPRMT6ADORA2AADORA2BP2RY12 | |
| SCHEMBL29792804 | 0.89 | TYMP (0.50) | TYMPPRMT6ADORA2AADORA2BP2RY12 | |
| SCHEMBL21305068 | 0.89 | TYMP (0.55) | TYMPPRMT6ADORA2AADORA2BP2RY12 | |
| SCHEMBL28356764 | 0.89 | TYMP (0.50) | TYMPPRMT6P2RY12ADORA1 | |
| SCHEMBL6396836 | 0.89 | TYMP (0.55) | TYMPPRMT6ADORA2AADORA2BP2RY12 | |
| SCHEMBL19493438 | 0.89 | TYMP (0.55) | TYMPPRMT6ADORA2AADORA2BP2RY12 | |
| SCHEMBL8381924 | 0.89 | TYMP (0.55) | TYMPPRMT6ADORA2AADORA2BP2RY12 | |
| SCHEMBL31419333 | 0.89 | TYMP (0.55) | TYMPPRMT6ADORA2AADORA2BP2RY12 | |
| SCHEMBL18797894 | 0.89 | TYMP (0.55) | TYMPPRMT6ADORA2AADORA2BP2RY12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3402801-B1 | CYCLIC DINUCLEOTIDES FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SUCH AS CANCER | INNATE TUMOR IMMUNITY INC (US) | 2025-08-06 | — | — | EP | disclosed |
| US-11505571-B2 | Compounds and compositions for treating conditions associated with sting activity | INNATE TUMOR IMMUNITY, INC. (US) | 2022-11-22 | — | — | US | disclosed |
| CN-109451740-B | Cyclic dinucleotides for the treatment of disorders associated with STING activity, such as cancer | 先天肿瘤免疫公司 | 2022-09-02 | — | — | CN | disclosed |
| US-20210147467-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | INNATE TUMOR IMMUNITY INC (US) | 2021-05-20 | — | — | US | disclosed |
| US-10961270-B2 | Compounds and compositions for treating conditions associated with sting activity | INNATE TUMOR IMMUNITY, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| US-20200165288-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | INNATE TUMOR IMMUNITY INC (US) | 2020-05-28 | — | — | US | disclosed |
| US-10604542-B2 | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | INNATE TUMOR IMMUNITY, INC. (US) | 2020-03-31 | — | — | US | disclosed |
| US-20190016750-A1 | CYCLIC DINUCLEOTIDES FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SUCH AS CANCER | Innate Tumoir Immunity, Inc. (US) | 2019-01-17 | — | — | US | disclosed |
| EP-3402801-A1 | CYCLIC DINUCLEOTIDES FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SUCH AS CANCER | Innate Tumor Immunity, Inc. (US) | 2018-11-21 | — | — | EP | disclosed |
| WO-2017123669-A1 | CYCLIC DINUCLEOTIDES FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SUCH AS CANCER | GLICK GARY (US) | 2017-07-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10961270-B2 | Compounds and compositions for treating conditions associated with sting activity | STING1, CGAS, IRF3 | TYMP 2613/4885PRMT6 2343/4885ADORA2A 481/4885 |
| US-20200165288-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | TYMP 2613/4885PRMT6 2343/4885ADORA2A 481/4885 |
| US-11505571-B2 | Compounds and compositions for treating conditions associated with sting activity | STING1, CGAS, IRF3 | TYMP 2613/4885PRMT6 2343/4885ADORA2A 481/4885 |
| US-10604542-B2 | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | STING1, CGAS, IRF3 | TYMP 112/4885PRMT6 1684/4885ADORA2A 503/4885 |
| US-20190016750-A1 | CYCLIC DINUCLEOTIDES FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY SUCH AS CANCER | STING1, CGAS, IRF3 | TYMP 112/4885PRMT6 1684/4885ADORA2A 503/4885 |
| US-20210147467-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | TYMP 2613/4885PRMT6 2343/4885ADORA2A 481/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.